Guardant Health, Inc. (NASDAQ:GH) Stock Holdings Lifted by California Public Employees Retirement System

California Public Employees Retirement System raised its stake in shares of Guardant Health, Inc. (NASDAQ:GH - Free Report) by 13.8% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 178,470 shares of the company's stock after buying an additional 21,674 shares during the quarter. California Public Employees Retirement System owned about 0.14% of Guardant Health worth $5,452,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of GH. R Squared Ltd purchased a new stake in shares of Guardant Health during the fourth quarter valued at $26,000. SBI Securities Co. Ltd. bought a new stake in shares of Guardant Health in the 4th quarter worth about $43,000. Kimelman & Baird LLC purchased a new position in Guardant Health in the 4th quarter worth about $58,000. Quantbot Technologies LP bought a new position in shares of Guardant Health during the fourth quarter valued at approximately $80,000. Finally, Jones Financial Companies Lllp boosted its position in shares of Guardant Health by 43.5% in the 4th quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company's stock worth $82,000 after purchasing an additional 817 shares in the last quarter. Hedge funds and other institutional investors own 92.60% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on GH shares. Barclays decreased their price objective on shares of Guardant Health from $60.00 to $55.00 and set an "overweight" rating on the stock in a report on Thursday. Scotiabank boosted their price objective on shares of Guardant Health from $47.00 to $52.00 and gave the company a "sector outperform" rating in a research note on Monday, February 24th. The Goldman Sachs Group upped their target price on shares of Guardant Health from $49.00 to $56.00 and gave the company a "buy" rating in a report on Friday, February 21st. Raymond James reiterated an "outperform" rating and set a $59.00 price objective (up previously from $39.00) on shares of Guardant Health in a research note on Friday, February 21st. Finally, Piper Sandler boosted their price target on Guardant Health from $34.00 to $50.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. Twenty investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of $49.00.

Remove Ads

Guardant Health Stock Performance

NASDAQ GH traded up $1.68 during trading hours on Monday, reaching $45.39. The stock had a trading volume of 157,694 shares, compared to its average volume of 2,135,159. The stock has a fifty day moving average of $43.57 and a 200 day moving average of $35.78. Guardant Health, Inc. has a 52-week low of $15.81 and a 52-week high of $50.89. The stock has a market cap of $5.60 billion, a P/E ratio of -12.75 and a beta of 1.45.

Guardant Health (NASDAQ:GH - Get Free Report) last posted its earnings results on Thursday, February 20th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.15). Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. The firm had revenue of $201.81 million for the quarter, compared to analyst estimates of $192.50 million. On average, equities research analysts forecast that Guardant Health, Inc. will post -2.9 EPS for the current year.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.